Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female children experiencing severe mouth pain secondary to chemotherapy induced mucositis requiring opioid analgesic therapy and who will be an inpatient, as a minimum up to Day 8 (patch removal).~2. Subjects experiencing 'severe' pain in the Investigators clinical judgment.~3. Body weight ≥ 15 kg. Subjects weighing ≥ 25 kg will be recruited in the first phase of the study with those weighing \< 25 kg also being included in the second phase, (after a successful review by an IDSMC). Upper age range to be 16 years.~4. In dwelling IV cannula or central line from which blood can be obtained.~5. Written informed consent obtained from parent(s)/legal representative, and where possible assent obtained from the subject if appropriate, in line with local regulations.~6. Females of child bearing potential must have a negative urine pregnancy test if the Principal Investigator considers there to be a reasonable possibility of pregnancy.~Exclusion criteria:~1. Subjects with known hypersensitivity to buprenorphine or any of its excipients in the transdermal system, as outlined in the Summary of Product Characteristics for BuTrans.~2. Known hypersensitivity to other opioids.~3. Skin disease affecting application or local tolerance of BTDS.~4. Clinically significant history of allergic reaction to wound dressings or adhesives.~5. Severe respiratory impairment.~6. Clinically significant hepatic dysfunction.~7. Severe renal impairment.~8. Subjects who are receiving MAO inhibitors or have taken them within the previous 2 weeks.~9. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with study medication.~10. Subjects who have taken any buprenorphine preparations in the last 14 days.~11. Subjects with myasthenia gravis.~12. Subjects with convulsive disorders, head injury, shock, or reduced level of consciousness of uncertain origin.~13. Subjects who are currently participating in another clinical research study involving a new chemical entity (NCE) unless the sole purpose of the other trial at the time of BUP1501 screening is for long term follow-up/survival data or subjects who have participated in a clinical study within the previous 30 days. Participation in a chemotherapy clinical trial that is not evaluating a NCE will be accepted for inclusion.~14. Subjects who are pregnant, lactating or in the Investigators opinion are at risk of conceiving.~15. Previous enrollment in this clinical study.~16. Subjects who the Investigator believes are unsuitable for the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Patch (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).